← AI Companies
Oscar Health is a technology-driven health insurance company that uses AI and data science to simplify insurance, personalize care, and improve healthcare outcomes.
Snapshot
| Country |
USA
|
| Exchange | NYSE |
| AI Layer |
app
|
| Sentiment |
58.0% |
| USD Mkt Cap | 10.11B |
| USD Revenue | 15.32B |
| USD Net Income | 550.74M |
| P/E | 25.02 |
| fwd P/E | 17.41 |
| Price 3M | +17.4% |
| Price 6M | +150.8% |
| Price 1Y | +71.6% |
| Price 2Y | +53.5% |
| USD Share Price | 33.17 |
Price & Size
| Price |
32.77 USD |
| Market Cap |
10.11B USD |
| Shares Outstanding |
273.47M |
| Shares Float |
263.19M |
| 52w Low |
10.69 USD |
| 52w High |
34.23 USD |
| Avg Volume |
5.44M |
Valuation
| P/E (trailing) |
25.0x |
| P/E (forward) |
17.4x |
| P/B |
4.92x |
| Enterprise Value |
2.03B USD |
| Book Value / Share |
6.66 USD |
| P/S |
0.66x |
| EV / Revenue |
0.13x |
| EV / EBITDA |
3.09x |
Income
| Revenue |
15.32B USD |
| Revenue / Share |
53.60 USD |
| EBITDA |
657.96M USD |
| Net Income |
550.74M USD |
| EPS (trailing) |
1.31 USD |
| EPS (forward) |
1.88 USD |
Margins & Profitability
| Gross Margin |
20.2% |
| Operating Margin |
8.0% |
| Profit Margin |
3.6% |
| EBITDA Margin |
4.3% |
| Return on Equity |
34.3% |
| Return on Assets |
4.5% |
Cash & Debt
| Total Cash |
8.56B USD |
| Total Debt |
482.10M USD |
| Free Cash Flow |
692.53M USD |
| Operating Cash Flow |
4.42B USD |
| Debt / Equity |
0.23x |
| Current Ratio |
1.08x |
| Quick Ratio |
1.05x |
Analyst Consensus
| Target (Mean) |
30.40 USD |
| Target (Median) |
28.50 USD |
| Target (High) |
39.00 USD |
| Target (Low) |
25.00 USD |
| Recommendation |
none |
| # Analysts |
10 |
Sentiment 58.0%
as of Sep 12, 2026
Positive drivers
Oscar Health reported stronger-than-expected membership growth in Q2 2026 driven by AI-powered underwriting and claims processing efficiencies. Positive analyst coverage highlighted the company's expanding partnerships with large employers and improved loss ratios. Stock price showed resilience amid broader AI sector rotation into healthcare tech names.
Neutral / mixed
Macroeconomic uncertainty around interest rates and healthcare policy changes created mixed signals for the sector. Trading volumes remained average with no major institutional accumulation or distribution patterns observed. Earnings guidance for the remainder of 2026 was in line with consensus estimates without significant beats or misses.
Negative drivers
Continued net losses and high customer acquisition costs weighed on investor sentiment despite revenue growth. Increased competition from larger insurers expanding into tech-enabled plans pressured margins. Regulatory scrutiny on AI use in insurance pricing introduced some overhang during the period.
Bottom line
Sentiment for OSCR remains mildly positive on AI-driven operational improvements but tempered by ongoing profitability challenges and competitive pressures. The 30-day window reflects cautious optimism rather than strong conviction buying.